

Kalos Therapeutics And Scientific Inventor Dr. David Vesely Featured On Good Morning America

Kalos Therapeutics announced today that the Company and the scientific inventor of its exclusively licensed technology to develop a family of heart hormones, a new therapy for the treatment of cancer, was featured today on Good Morning America.

Dec. 1, 2009 - [PRLog](#) -- SAN DIEGO, CA –Kalos Therapeutics, Inc. announced today that the Company and the scientific inventor of its exclusively licensed technology to develop a family of heart hormones known as ANP (atrial natriuretic peptide) a new therapy for the treatment of cancer, was featured today on Good Morning America. This GMA interview can be accessed at:

<http://abcnews.go.com/video/playerIndex?id=9215291>

The segment is titled “Did a Devoted Husband Find a Cancer Breakthrough?”

Throughout his years of groundbreaking research, endocrinologist Dr. David Vesely never gave curing cancer a lot of thought. But then it became personal. "We started to work on cancer when my wife died of breast cancer seven years ago," Vesely said.

His wife, Clo, died in 2002, leaving Vesely and their five children behind. Vesely said he directed his sorrow into his work at the James A. Haley Hospital in Tampa, Fla., and seven years later he may have a breakthrough.

An Idea From the Heart

Vesely said it was originally his son's idea to conduct research. Brian, who was 16 when his mother died, was looking for a way to channel his grief a month after his mother's death.

In the late 1980s, Vesely, focusing on heart disease, discovered three hormones made by the heart that prevented normal heart cells from getting bigger and multiplying. He wondered if they could also control cancer cell growth.

Vesely and Brian set up an experiment and left cancer cells and heart hormones alone in a Petri dish. The cancer cells were blown apart by the body's own hormones.

"Well, the cells blew apart. So we thought, 'maybe we did something wrong,'" Vesely said. "Because you never know ... but the second time, we knew it was real."

Vesely began studying the effect on mice that had been injected with human cancer cells, by pumping the hormones under their skin.

"Usually after a month, they eliminate up to 80 percent of human pancreatic cancers growing in the mice," Vesely said.

Since then Vesely said he has eliminated other deadly forms of human cancers in mice, including 67 percent of breast cancers and 86 percent of small cell lung cancers, all with almost no side effects.

Although Vesely, 66, said he wouldn't go as far as to call it a cure for cancer, he is hopeful.

"But if it does cure one cancer in human, it will cure almost all of them, or eliminate them," Vesely said.

Vesely's Finding Met With Hope and Caution

Vesely published his work, and although the medical world is intrigued, it is also cautious.

"I think that there's potentially promise here, but I think the real question is whether these very potent hormones will be tolerable at the doses required," said Dr. Mark Ratain from the University of Chicago.

Human Clinical Trials to Begin

Kalos Therapeutics is raising money for the first human clinical trials for Vesely's findings. But as Vesely waits, he said he is feeling the urgency from hundreds of e-mails from people dying of cancer asking when his treatment will be ready.

"It's mostly funding. They need money to move ahead," Vesely said.

"If we can make some dent in cancer ... it will be spectacular," Vesely added.

About Kalos:

Kalos Therapeutics (www.kalostpx.com) is an emerging drug development company with an exclusive patent to develop the ANP (atrial natriuretic peptide) family of peptides as a new therapy for the treatment of cancer. Kalos is pioneering a unique approach to cancer treatment by developing native peptides derived from the human heart as cytostatic therapeutic compounds to treat aggressive cancers by engaging known pathway receptors more efficiently without impacting patients with the side effects associated with chemotherapeutic or small molecule compounds. While there are many companies pursuing new approaches to cancers therapies, none are currently exploring the cardio-renal axis. ANP peptides are designed by nature to inhibit the MAPK pathway by controlling initiation of the signaling cascade while synthetic drugs block only specific parts of the pathway. Supporting the inherent anti-cancer properties of ANP is the rarity of primary and metastatic cancers in the heart, where these peptides are at their highest concentrations. Kalos Therapeutics is devoted to treating the unmet needs of people living with incurable diseases through discovery, research, and development of non-toxic endogenous peptide therapies.

Contact:

Kalos Therapeutics, Inc.
George E. Colberg, Jr.
(858) 385-1290
gcolberg@kalostpx.com

###

About Kalos:

Kalos Therapeutics (<http://www.kalostpx.com>) is an emerging drug development company with an exclusive patent to develop the ANP (atrial natriuretic peptide) family of peptides as a new therapy for the treatment of cancer. Kalos is pioneering a unique approach to cancer treatment by developing native peptides derived from the human heart as cytostatic therapeutic compounds to treat aggressive cancers by engaging known pathway receptors more efficiently without impacting patients with the side effects associated with chemotherapeutic or small molecule compounds. While there are many companies pursuing new approaches to cancers therapies, none are currently exploring the cardio-renal axis. Supporting the

inherent anti-cancer properties of ANP is the rarity of primary and metastatic cancers in the heart, where these peptides are at their highest concentrations.

--- End ---

Source Kalos Therapeutics, Inc.
City/Town San Diego
State/Province California
Zip 92122
Country United States
Industry [Health](#), [Science](#)
Tags [Cancer](#), [Biotechnology](#), [Drug Development](#), [Peptides](#), [Kalos Therapeutics](#), [Good Morning America](#),
[Dr David Vesely](#)
Link <https://prlog.org/10434907>



Scan this QR Code with your SmartPhone to-

- * Read this news online
- * Contact author
- * Bookmark or share online